KR102443942B1 - 외상성 뇌 손상에 대한 글리세릴 3-하이드록시부티레이트 - Google Patents
외상성 뇌 손상에 대한 글리세릴 3-하이드록시부티레이트 Download PDFInfo
- Publication number
- KR102443942B1 KR102443942B1 KR1020197020924A KR20197020924A KR102443942B1 KR 102443942 B1 KR102443942 B1 KR 102443942B1 KR 1020197020924 A KR1020197020924 A KR 1020197020924A KR 20197020924 A KR20197020924 A KR 20197020924A KR 102443942 B1 KR102443942 B1 KR 102443942B1
- Authority
- KR
- South Korea
- Prior art keywords
- hydroxybutyrate
- glyceryl
- tbi
- ester
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000030886 Traumatic Brain injury Diseases 0.000 title claims abstract description 133
- 230000009529 traumatic brain injury Effects 0.000 title claims abstract description 131
- CBTHKODKAPVTNY-UHFFFAOYSA-N 2,3-dihydroxypropyl 3-hydroxybutanoate Chemical compound CC(O)CC(=O)OCC(O)CO CBTHKODKAPVTNY-UHFFFAOYSA-N 0.000 title claims 7
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 40
- 230000000414 obstructive effect Effects 0.000 claims abstract description 13
- 238000011477 surgical intervention Methods 0.000 claims abstract 10
- -1 glyceryl (3-hydroxybutyrate) ester Chemical class 0.000 claims description 86
- 235000020887 ketogenic diet Nutrition 0.000 claims description 62
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 50
- 150000002576 ketones Chemical class 0.000 claims description 47
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 44
- 239000007983 Tris buffer Substances 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 37
- 230000006378 damage Effects 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 201000001421 hyperglycemia Diseases 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 15
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims description 15
- 239000008103 glucose Substances 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 150000001720 carbohydrates Chemical class 0.000 claims description 13
- 235000014633 carbohydrates Nutrition 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 235000003642 hunger Nutrition 0.000 claims description 10
- 230000037351 starvation Effects 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 8
- 230000036470 plasma concentration Effects 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 7
- 230000002085 persistent effect Effects 0.000 claims description 7
- 230000001052 transient effect Effects 0.000 claims description 6
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical group CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 244000144972 livestock Species 0.000 claims description 2
- 235000021590 normal diet Nutrition 0.000 claims 14
- 230000007062 hydrolysis Effects 0.000 claims 5
- 238000006460 hydrolysis reaction Methods 0.000 claims 5
- 210000004958 brain cell Anatomy 0.000 claims 3
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical group CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 claims 2
- 230000000149 penetrating effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 claims 1
- 239000013590 bulk material Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 description 28
- 208000014674 injury Diseases 0.000 description 28
- 206010010254 Concussion Diseases 0.000 description 25
- 235000005911 diet Nutrition 0.000 description 25
- 230000009514 concussion Effects 0.000 description 24
- 230000037213 diet Effects 0.000 description 24
- 208000004209 confusion Diseases 0.000 description 13
- 206010013395 disorientation Diseases 0.000 description 13
- 206010010071 Coma Diseases 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 230000003087 glucogenic effect Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000011867 re-evaluation Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 7
- 208000007976 Ketosis Diseases 0.000 description 6
- 235000021196 dietary intervention Nutrition 0.000 description 6
- 206010015037 epilepsy Diseases 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 208000019695 Migraine disease Diseases 0.000 description 5
- AOWPVIWVMWUSBD-RNFRBKRXSA-N [(3r)-3-hydroxybutyl] (3r)-3-hydroxybutanoate Chemical compound C[C@@H](O)CCOC(=O)C[C@@H](C)O AOWPVIWVMWUSBD-RNFRBKRXSA-N 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000035861 hyperketonemia Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 150000004667 medium chain fatty acids Chemical class 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000025978 Athletic injury Diseases 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 208000003443 Unconsciousness Diseases 0.000 description 4
- 235000020827 calorie restriction Nutrition 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002361 ketogenic effect Effects 0.000 description 4
- 230000004140 ketosis Effects 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 206010019196 Head injury Diseases 0.000 description 3
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 229940057917 medium chain triglycerides Drugs 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 2
- 206010000410 Acetonaemia Diseases 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 235000021074 carbohydrate intake Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 235000021085 polyunsaturated fats Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- WTKMPKREPYCDPG-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-hydroxybutanoate Chemical class CCC(O)C(=O)OCC(O)CO WTKMPKREPYCDPG-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 235000021084 monounsaturated fats Nutrition 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/404,396 | 2017-01-12 | ||
| US15/404,396 US9925164B1 (en) | 2017-01-12 | 2017-01-12 | Glyceryl 3-hydroxybutyrates for traumatic brain injury |
| PCT/US2017/063853 WO2018132189A1 (en) | 2017-01-12 | 2017-11-30 | Glyceryl 3-hydroxybutyrates for traumatic brain injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190104546A KR20190104546A (ko) | 2019-09-10 |
| KR102443942B1 true KR102443942B1 (ko) | 2022-09-15 |
Family
ID=61633011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197020924A Active KR102443942B1 (ko) | 2017-01-12 | 2017-11-30 | 외상성 뇌 손상에 대한 글리세릴 3-하이드록시부티레이트 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9925164B1 (https=) |
| EP (1) | EP3568129A4 (https=) |
| JP (1) | JP7278593B2 (https=) |
| KR (1) | KR102443942B1 (https=) |
| CN (1) | CN110114067A (https=) |
| BR (1) | BR112019014128A2 (https=) |
| CA (1) | CA3046355C (https=) |
| IL (1) | IL267934B2 (https=) |
| MX (1) | MX391851B (https=) |
| MY (1) | MY207193A (https=) |
| WO (1) | WO2018132189A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12521378B2 (en) | 2016-04-19 | 2026-01-13 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans |
| US20230346721A1 (en) | 2018-04-18 | 2023-11-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| CA3021784A1 (en) * | 2016-04-19 | 2017-10-26 | Keto Patent Group, Inc. | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| US12599579B2 (en) | 2016-04-19 | 2026-04-14 | Axcess Global Sciences, Llc | Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids |
| US12533346B2 (en) | 2016-04-19 | 2026-01-27 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
| US10376528B2 (en) | 2017-03-10 | 2019-08-13 | Tecton Group, Llc | Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor |
| US12171735B2 (en) | 2017-04-19 | 2024-12-24 | Axcess Global Sciences, Llc | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans |
| GB201715654D0 (en) | 2017-09-27 | 2017-11-08 | Tdeltas Ltd | Method of treatment |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| BR112021014012A2 (pt) * | 2019-01-17 | 2021-09-21 | Ioi Oleo Gmbh | Processo para a produção de lipídeos que contêm unidades estruturais com base em glicerídeos de ácidos hidroxicarboxílicos |
| ES2941943T3 (es) * | 2019-01-17 | 2023-05-26 | Ketolipix Therapeutics Gmbh | Método para la producción de glicéridos de ácidos hidroxicarboxílicos |
| US12472200B2 (en) | 2019-05-15 | 2025-11-18 | Axcess Global Sciences, Llc | Autobiotic compositions and method for promoting healthy gut microbiome |
| PL3976021T3 (pl) * | 2019-05-30 | 2025-07-21 | Neuroenergy Ventures, Inc. | Tri(beta-hydroksymaślan) glicerolu do zastosowania w leczeniu i zapobieganiu przemijającym atakom niedokrwiennym neuronów |
| US20230020342A1 (en) * | 2019-06-12 | 2023-01-19 | Ioi Oleo Gmbh | Method for producing polyol-based esters, in particular polyglycerol esters, from hydroxy carboxylic acids |
| JP7546828B2 (ja) * | 2019-06-12 | 2024-09-09 | ケトリピックス セラポーティクス ゲーエムベーハー | ケトカルボン酸のポリオールベースのエステルの製造方法 |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| EP4146337B1 (de) * | 2020-07-13 | 2024-04-17 | KetoLipix Therapeutics GmbH | Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren |
| US12186297B2 (en) | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| EP4366720A4 (en) * | 2021-07-09 | 2025-05-07 | Georgia State University Research Foundation, Inc. | The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections |
| MX2024005533A (es) | 2021-11-12 | 2024-07-29 | Arxada Ag | Compuestos derivados de polioles. |
| US20250002446A1 (en) | 2021-11-26 | 2025-01-02 | Arxada Ag | Acetoacetate Based Ketals |
| US12023382B2 (en) | 2022-01-18 | 2024-07-02 | Today Inc. | Molecules, formulations, and methods for nutritional support of athletes, patients, and others |
| WO2023139357A1 (en) * | 2022-01-18 | 2023-07-27 | Today Inc. | Molecules, nutritional formulations, and methods of providing nutritional support |
| US20230277484A1 (en) * | 2022-03-04 | 2023-09-07 | Guardian Biosciences, LLC | Compositions and methods to promote brain health |
| WO2024083889A1 (en) | 2022-10-18 | 2024-04-25 | Arxada Ag | Polyol-derived compounds |
| WO2025074001A2 (en) | 2023-10-05 | 2025-04-10 | Arxada Ag | Enzymatic reduction of acetoacetate |
| WO2025196156A1 (en) | 2024-03-20 | 2025-09-25 | Arxada Ag | Continuous hydrogenation process of acetoacetate esters |
| WO2025224319A1 (en) | 2024-04-25 | 2025-10-30 | Arxada Ag | Reduction of acetoacetate esters in the presence of amines |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008005818A1 (en) * | 2006-06-30 | 2008-01-10 | Stepan Co | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| WO2011101171A1 (en) | 2010-02-22 | 2011-08-25 | Tdeltas Limited | Nutritional composition |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4598203B2 (ja) * | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
| US6323237B1 (en) | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| CA2283642C (en) * | 1997-03-17 | 2012-05-15 | Btg International Limited | Therapeutic compositions |
| US8124589B2 (en) | 2000-05-01 | 2012-02-28 | Accera, Inc. | Use of ketogenic compounds for treatment of age-associated memory impairment |
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| WO2006128006A1 (en) | 2005-05-26 | 2006-11-30 | The Regents Of The University Of Colorado | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| BRPI0811052A2 (pt) | 2007-04-12 | 2015-01-27 | Univ Minnesota | Composições de proteção de isquemia/reperfusão e métodos de uso. |
| JP2009173766A (ja) | 2008-01-24 | 2009-08-06 | Ono Kogei Kk | 炭素繊維含有コーティング組成物およびその調製方法 |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| WO2010084356A1 (en) | 2009-01-24 | 2010-07-29 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
| CA2873057C (en) | 2011-05-09 | 2020-02-25 | University Of South Florida | The use of ketone esters for prevention of cns oxygen toxicity |
| US20140072654A1 (en) | 2011-12-23 | 2014-03-13 | Savind, Inc. | Cancer with metabolic therapy and hyperbaric oxygen |
| FR2997302B1 (fr) | 2012-10-29 | 2015-02-06 | Assist Publ Hopitaux De Paris | Prevention et traitement des deficits en pyruvate deshydrogenase |
| EP2914251B1 (en) | 2012-11-05 | 2019-08-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Ketone bodies to protect tissues from damage by ionizing radiation |
| WO2014085652A1 (en) | 2012-11-28 | 2014-06-05 | University Of South Florida | Targeting cancer with metabolic therapy and hyperbaric oxygen |
| KR102499654B1 (ko) | 2013-03-19 | 2023-02-13 | 유니버시티 오브 사우스 플로리다 | 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법 |
| WO2015034812A2 (en) * | 2013-09-04 | 2015-03-12 | Beth Israel Deaconess Medical Center | A new ketogenic diet and its use in treating the critically ill |
| WO2015156865A1 (en) | 2014-01-13 | 2015-10-15 | University Of South Florida | Methods of sustaining dietary ketosis and its effects on lipid profile |
| US20160078782A1 (en) | 2014-09-17 | 2016-03-17 | The Trustees Of Boston College | Glucose Ketone Index for MetabolicTherapy |
| US9364456B1 (en) | 2015-06-30 | 2016-06-14 | University Of South Florida | Ketone esters for treatment of angelman syndrome |
| US20180200220A1 (en) | 2015-07-10 | 2018-07-19 | Cognate Nutritionals, Inc. | Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources |
| US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| WO2017165445A1 (en) | 2016-03-21 | 2017-09-28 | Csilla Ari D'agostino | Administration of exogenous ketone to lower blood glucose |
| US10376482B2 (en) | 2016-04-03 | 2019-08-13 | Franco Cavaleri | Butyrate and beta-hydroxybutyrate compositions |
| CA3021784A1 (en) | 2016-04-19 | 2017-10-26 | Keto Patent Group, Inc. | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
| WO2018009208A1 (en) | 2016-07-08 | 2018-01-11 | Cognate Nutritionals, Inc. | Nutritional mitiggation of the cns effects of traumatic brain injury |
| US10588877B2 (en) | 2016-07-21 | 2020-03-17 | Savind, Inc. | Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same |
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| US20180055797A1 (en) | 2016-08-31 | 2018-03-01 | KetoneAid Inc. | Non-racemic ketone salts for rapid-onset nutritional ketosis and metabolic therapy |
| CN109890381A (zh) | 2016-09-12 | 2019-06-14 | 南佛罗里达大学 | 酮改善神经再生 |
-
2017
- 2017-01-12 US US15/404,396 patent/US9925164B1/en active Active
- 2017-11-30 IL IL267934A patent/IL267934B2/en unknown
- 2017-11-30 JP JP2019536598A patent/JP7278593B2/ja active Active
- 2017-11-30 BR BR112019014128-6A patent/BR112019014128A2/pt not_active Application Discontinuation
- 2017-11-30 CA CA3046355A patent/CA3046355C/en active Active
- 2017-11-30 EP EP17891194.7A patent/EP3568129A4/en active Pending
- 2017-11-30 WO PCT/US2017/063853 patent/WO2018132189A1/en not_active Ceased
- 2017-11-30 KR KR1020197020924A patent/KR102443942B1/ko active Active
- 2017-11-30 CN CN201780080457.XA patent/CN110114067A/zh active Pending
- 2017-11-30 MY MYPI2019003665A patent/MY207193A/en unknown
- 2017-11-30 MX MX2019008269A patent/MX391851B/es unknown
-
2018
- 2018-03-01 US US15/909,240 patent/US10736867B2/en active Active
-
2020
- 2020-06-10 US US16/897,349 patent/US11638702B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008005818A1 (en) * | 2006-06-30 | 2008-01-10 | Stepan Co | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| WO2011101171A1 (en) | 2010-02-22 | 2011-08-25 | Tdeltas Limited | Nutritional composition |
Non-Patent Citations (2)
| Title |
|---|
| Critical Care, 15(219), 1-10, 2011.* |
| Journal of Lipid Research, 55(12), 2450-2457, 2014. |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3568129A4 (en) | 2020-12-09 |
| US9925164B1 (en) | 2018-03-27 |
| IL267934B2 (en) | 2024-09-01 |
| BR112019014128A2 (pt) | 2020-06-16 |
| JP2020504134A (ja) | 2020-02-06 |
| CN110114067A (zh) | 2019-08-09 |
| WO2018132189A1 (en) | 2018-07-19 |
| CA3046355A1 (en) | 2018-07-19 |
| US20180193300A1 (en) | 2018-07-12 |
| US20200297686A1 (en) | 2020-09-24 |
| IL267934B1 (en) | 2024-05-01 |
| MX2019008269A (es) | 2019-09-13 |
| MY207193A (en) | 2025-02-05 |
| CA3046355C (en) | 2023-08-01 |
| IL267934A (en) | 2019-09-26 |
| MX391851B (es) | 2025-03-21 |
| EP3568129A1 (en) | 2019-11-20 |
| JP7278593B2 (ja) | 2023-05-22 |
| KR20190104546A (ko) | 2019-09-10 |
| US10736867B2 (en) | 2020-08-11 |
| US11638702B2 (en) | 2023-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102443942B1 (ko) | 외상성 뇌 손상에 대한 글리세릴 3-하이드록시부티레이트 | |
| Antushevich | Fecal microbiota transplantation in disease therapy | |
| US9364456B1 (en) | Ketone esters for treatment of angelman syndrome | |
| JP2020504134A5 (https=) | ||
| Jovanovic-Peterson et al. | Exercise and the nutritional management of diabetes during pregnancy | |
| JP2020514338A (ja) | 対象におけるマイトファジーを改善するための方法 | |
| Sears et al. | Therapeutic uses of high-dose omega-3 fatty acids to treat comatose patients with severe brain injury | |
| WO2016013617A1 (ja) | 脳機能改善剤、及び認知機能障害の予防または治療剤 | |
| Saleh-Ghadimi et al. | Effect of flaxseed oil supplementation on anthropometric and metabolic indices in patients with coronary artery disease: a double-blinded randomized controlled trial | |
| Veggiotti et al. | The ketogenic diet for Dravet syndrome and other epileptic encephalopathies: an Italian consensus | |
| Keskin et al. | Protein substitutions as new-generation pharmanutrition approach to managing phenylketonuria | |
| WO2000009138A1 (en) | Nutritional compositions for preventing or treating hyperlipoproteinemia | |
| Edwards et al. | Diet-induced ketosis in adult patients with subacute acquired brain injury: a feasibility study | |
| ES2398847T3 (es) | Composición que comprende uno o más fitoesteroles y/o fitoestanoles y glucomanano y usos de la composición para tratar trastornos de lípidos en individuos con y sin diabetes de tipo II | |
| Sánchez-Pintos et al. | Intravenous branched-chain amino-acid-free solution for the treatment of metabolic decompensation episodes in Spanish pediatric patients with maple syrup urine disease | |
| Lane et al. | Ketogenic diet and health | |
| Lim et al. | Effect of nutritional intervention on nutritional status among children with disorders of amino acid and nitrogen metabolism (AANMDs): A scoping review | |
| Rattanachaiwong et al. | A high-protein peptide-based enteral formula improves diarrhea in tube-fed patients: A prospective multicenter study | |
| Kuźniar et al. | Ketogenic diet and intermittent fasting-impact on body weight and various diseases | |
| Camões et al. | Super-refractory status epilepticus and ketogenic diet in intensive care: a series report | |
| HK40012461A (en) | Glyceryl 3-hydroxybutyrates for traumatic brain injury | |
| Calcaterra et al. | Breastfeeding and maternal exercise: A synergistic approach to improve cardiometabolic health | |
| Pawłowski et al. | Hypervitaminosis D in the pediatric population | |
| Mohammed et al. | Successful Management of Severe Hypertriglyceridemia in a Neonate with Apolipoprotein A Deficiency: A Case Report with Literature Review | |
| JOHNSON et al. | Ketogenic Diet Therapies in Adults |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190717 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201130 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220504 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220901 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20220913 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20220913 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20250320 Start annual number: 4 End annual number: 4 |